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Abstract
Sustained ventricular tachycardia (VT) is an important cause of morbidity and sudden death in 
patients with dilated cardiomyopathy. Although ICD effectively terminate VT episodes and 
improve survival, shocks reduce quality of life, and episodes of VT predict increased risk of 
heart  failure  and death  despite  effective  therapy.  Patients  suffering recurrent  VT episodes 
remain  a  challenge.  Antiarrhytmic  therapy reduces  VT episodes,  but  it  is  associated  with 
serious  adverse  events,  and  disappointing  efficacy.  Catheter  ablation  has  emerged  as  an 
important option to control recurrent VT, but major procedure-related complications, and even 
death, are still issues to concern. And even with these armamentaria, some patients still have 
recurrent VT episodes and ICD shocks.  We report  on a patient  with non-ischemic dilated 
cardiomyopathy  and  recurrent  ventricular  tachycardia  resistant  to  multiple  antiarrhytmic 
agents, in whom dronedarone was effective in completely suppressing ventricular tachycardia 
episodes.
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Background
Sustained ventricular tachycardia (VT) is an important cause of morbidity and sudden death in 
patients with dilated cardiomyopathy. Although ICDs effectively terminate VT episodes and 
improve survival, shocks reduce quality of life, and episodes of VT predict increased risk of 
heart  failure  and death  despite  effective  therapy.  Patients  suffering recurrent  VT episodes 
remain a challenge.  Antiarrhythmic therapy reduces VT episodes, but it  is associated with 
serious  adverse  events,  and  disappointing  efficacy.  Catheter  ablation  has  emerged  as  an 
important option to control recurrent VT, but major procedure-related complications, and even 
death, are still issues of concern. And even with this armamentarium, some patients still have 
recurrent VT episodes and ICD shocks.  We report  on a patient  with non-ischemic dilated 
cardiomyopathy  and  recurrent  ventricular  tachycardia  resistant  to  multiple  antiarrhythmic 
agents, in whom dronedarone was effective in completely suppressing ventricular tachycardia 
episodes.
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Case  Report                                  
An 81-year-old man with non-ischemic dilated cardiomyopathy and severe ventricular systolic 
dysfunction (EF 30%) underwent biventricular ICD implantation (St Jude Promote AccelTM), 
after suffering sudden cardiac death due to ventricular tachycardia. Baseline rhythm was atrial 
fibrillation  with  slow  ventricular  response.  He  was  on  amiodarone,  beta-blocker  and 
angiotensin receptor blocker at the time of implantation, without heart failure symptoms.      
The patient  continued to have symptomatic  VT episodes with appropriate  ICD discharges. 
Amiodarone was increased, but it was discontinued due to severe hypothyroidism. He was 
placed  on  sotalol  80  mg  twice  a  day,  but  soon  stopped  after  patient  developed  QT 
prolongation and asthenia. Patient was switched to propafenone 300 mg 3 times daily, but 
again side effects (diarrhea, nausea-vomiting) led to therapy discontinuation. Symptomatic VT 
episodes with multiple morphologies requiring ICD discharges and/or emergency room visits 
continued,  despite  optimization  of  ATP  therapy.                             
Procainamide  was  initiated  with  better  tolerance,  although  patient  continued  to  be 
symptomatic with frequent VT episodes. At this point in time, an echocardiogram showed 
marked left ventricular systolic function impairment (EF 15%). Of note, cardiac function in 
consecutive echocardiograms had initially remained stable after ICD implantation. The rest of 
pharmacological agents had not been modified. After myocardial ischemia was ruled out, a 
catheter  ablation  procedure  was  planned,  but  patient  refused  invasive  procedures.  Trying 
dronedarone was offered,  with clear  understanding of its  off-label  and compassionate use. 
After informed consent, patient was switched to droneradone 400 mg twice daily. On follow-
up, patient reported significant improvement of his symptoms, with just one episode of VT 
successfully treated with ATP therapy over the next 12 months, and systolic function recovery 
to prior 30% coinciding with the decrease of arrhythmic burden. Significant reduction of ICD 
shocks before and after droneradone initiation is shown in Figure 1.
Figure 1
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Discussion
Droneradone represents the latest generation of antiarrhythmic drugs, a multichannel blocking 
agent with molecular structure similar to amiodarone, but with a more favorable safety profile, 
as  the  drug  is  no  iodinated  and  has  less  lipophilicity  [1],  The  possibility  to  overcome 
extracardiac effects of long-term treatment with amiodarone in AF patients seemed particularly 
promising, as clinical studies had shown that dronedarone effectively reduces ventricular rate 
and  may  prevent  or  delay  the  recurrence  of  AF.  Even  more,  the  ATHENA  trial  showed 
significant  reductions  in  a  composite  end  point  of  all-cause  mortality  and  cardiovascular 
hospitalization  with  dronedarone  use,  and  a  post  hoc  analysis  of  the  ATHENA  data  also 
suggested a decrease in stroke risk with this agent [2,3]. This initial enthusiastic state drove to 
droneradone incorporation into American College of Cardiology Foundation (ACCF)/American 
Heart Association (AHA)/Heart Rhythm Society (HRS), and European Society of Cardiology 
(ESC)  2010  guidelines  on  AF,  even  as  a  drug  of  first-line  treatment  in  the  latter  [4]. 
Unfortunately,  droneradone  is  clearly  less  effective  in  maintaining  sinus  rhythm  than 
amiodarone, and, although significantly safer, recently FDA and EMA recommended warnings 
about  possible  risk  of  severe  liver  injury.                                     
Dronedarone  has  not  been  specifically  studied  for  patients  with  ventricular  arrhythmias. 
However,  animal  studies  have  demonstrated  antiarrhytmic  properties  on  ventricular 
myocardium, and clinical experience may suggest it  may be an alternative in selected cases 
[5,6].  In  ATHENA trial  patients  on  droneradone  showed  a  reduction  in  arrhythmic  death. 
Kowey  et  al  reported  a  trend  towards  reduction  in  appropriate  ICD shocks  in  patients  on 
droneradone at high doses. Although this indication is not established, positive experience is 
accumulating in this setting. Fink et al reported suppression of VT episodes as read in device 
memory over 6 months follow-up in a patient with paroxysmal AF, ischemic cardiomyopathy 
and ICD implantation due to ventricular arrhythmias. Dronedarone was started as alternative to 
amiodarone because of intolerance [7]. Finally, Shaaraoui et al described recently suppression 
of recurrent ventricular tachycardia refractory to multiple drug therapy and catheter ablation in a 
DCM  patient  with  mild  ventricular  dysfunction  and  no  signs  of  heart  failure  [8].     
Use of droneradone in severely depressed ventricular function remains controversial, as its use 
in congestive heart  failure patients  may lead to worsening symptoms and even cardiogenic 
shock [9]. In the ANDROMEDA trial, dronedarone was associated with increased mortality 
when  tested  in  New York  Heart  Association  (NYHA)  III/IV  patients  with  left  ventricular 
ejection fractions of less than 35%, who also had a recent hospitalization for decompensated 
heart  failure.                                    
In  our  case,  droneradone  suppressed  dramatically  the  number  of  VT  episodes,  without 
impairing  heart  failure  symptoms,  and  even  restoring  ventricular  function  to  baseline, 
presumably due to the mid-term adverse consequences of frequent ventricular ectopy and runs 
of  non-sustained  and  sustained  VT.                                    
Although no definitive conclusions can be made with so few cases, the notion of a potential role 
for  droneradone  in  controlling  ventricular  arrhythmias  merits  further  exploration.       
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